Brief: Notable Labs Presents The Design Plan For The PPMP-Enabled Phase 2 Trial With Volasertib For Relapsed/Refractory AML At AACR 2024
09/04/2024 23:27
April 9 (Reuters) - Notable Labs Ltd NTBL.O :
* NOTABLE LABS PRESENTS THE DESIGN PLAN FOR THE PPMP-ENABLED
PHASE
2 TRIAL WITH VOLASERTIB FOR RELAPSED/REFRACTORY AML AT AACR 2024
Source text for Eikon: ID:nGNX8zSfC1
Further company coverage: NTBL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives